局限性前列腺癌各治疗方式的泌尿系统不良事件风险演变:SEER-Medicare倾向加权分析
18年时UAE风险最高为RP+EBRT(41%),最低为BT(22%);调整后无UAE生存期最短为RP+EBRT(13.1年),最长为BT(15.8年)。
要点
- 联合治疗UAE风险最高,RP+EBRT的18年UAE风险达41%。
- BT单药UAE风险最低(22%),无UAE生存期最长(15.8年)。
- 与RP相比,RP+EBRT的无UAE生存期缩短2.0年(RMST比值0.87)。
核心结论
- 不同局限性前列腺癌治疗的长期泌尿系统不良事件风险存在时间依赖性差异,联合治疗风险最高。
主要发现
- 18年UAE累积风险:RP+EBRT 41%,BT+EBRT 35%,EBRT 29%,RP 23%,BT 22%。
- 调整后18年无UAE生存期:RP+EBRT 13.1年,BT 15.8年,消融15.6年,RP 15.1年。
- 与RP相比,RP+EBRT的无UAE生存期缩短2.0年(RMST比值0.87;p<0.001)。
- 与RP相比,EBRT+BT的无UAE生存期缩短0.2年(RMST比值0.99;p<0.001)。
临床怎么用
- 治疗选择需平衡肿瘤疗效与长期泌尿系统毒性,联合治疗应谨慎评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate cancer treatments can cause long-term urinary adverse events (UAEs), but time-varying risks across treatments remain understudied. Using Surveillance, Epidemiology and End Results-Medicare data, we evaluated men aged ≥66 yr with localized prostate cancer treated with radical prostatectomy (RP), external beam radiotherapy (EBRT), brachytherapy (BT), EBRT + BT, RP + EBRT, or ablation between 2000 and 2017. The primary outcome was any UAE requiring a procedure, with follow-up from treatment initiation and censoring at disease progression. Kaplan-Meier analysis was used to estimate the UAE cumulative incidence and the propensity-weighted restricted mean survival time (RMST) to quantify mean UAE-free survival at 18 yr. The cohort included 166 581 patients: 40% received EBRT, 30% RP, 14% BT + EBRT, 12% BT, 3.1% RP + EBRT, and 1.7% ablation. Combined therapy carried the highest risk, with other modalities showing time-dependent changes. At 18 yr, the UAE risk was highest for RP + EBRT (41%), followed by BT + EBRT (35%), EBRT (29%), RP (23%), and BT (22%). Adjusted RMST to 18 yr was shortest for RP + EBRT (13.1 yr) and longest for BT (15.8 yr) and ablation (15.6 yr). In comparison to RP (15.1 yr), UAE-free survival was 2.0 yr shorter with RP + EBRT (RMST ratio 0.87; p < 0.001) and 0.2 yr shorter with EBRT + BT (RMST ratio 0.99; p < 0.001). The balance between oncologic efficacy and long-term urinary toxicity is key to treatment selection.
引用
- Li KD, Carlisle MN, Jarosek S, et al. Evolving Risk of Urinary Adverse Events Across Localized Prostate Cancer Treatments: A Propensity-weighted Analysis of Surveillance, Epidemiology and End Results-Medicare Data. Eur Urol. 2025. PMID: 40410019. doi:10.1016/j.eururo.2025.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。